# Ultragenyx Pharmaceutical Inc.
Who / What
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company specializing in the research and development of innovative treatments for rare and ultra-rare genetic diseases—conditions often lacking approved therapies and presenting high unmet medical needs. The company explores multiple drug modalities, including biologics, small molecules, gene therapies, antisense oligonucleotides (ASOs), and mRNA-based approaches across disease categories such as bone disorders, endocrine/metabolic conditions, muscle diseases, and central nervous system (CNS) illnesses.
---
Background & History
Ultragenyx was founded in 2013 with a mission to address severe genetic diseases through cutting-edge biopharmaceutical innovation. The company emerged from the need to develop targeted therapies for patients affected by rare conditions, many of which were previously untreatable or had limited options. Early milestones included strategic partnerships and investments aimed at accelerating drug discovery in underserved therapeutic areas. Over time, Ultragenyx expanded its pipeline with a focus on precision medicine, leveraging advancements in genetic research and biotechnology.
---
Why Notable
Ultragenyx stands out for its commitment to treating ultra-rare diseases that disproportionately affect children and adults with severe genetic disorders. By pioneering novel drug modalities—such as gene-editing approaches and ASOs—the company has demonstrated a track record of advancing therapies that were previously deemed unattainable. Its work in metabolic, neuromuscular, and endocrine diseases has garnered attention for its potential to transform patient outcomes in underserved populations. The company’s collaborative approach with academic institutions and industry partners further underscores its innovative leadership in the biopharmaceutical space.
---
In the News
Ultragenyx continues to gain prominence as it progresses several high-potential therapies, including those targeting lysosomal storage diseases (LSDs) and other rare genetic conditions. Recent developments have highlighted its efforts to expand access to treatments for patients globally, with ongoing clinical trials and regulatory submissions driving media coverage of its advancements in gene-editing and mRNA-based medicines. The company’s focus on addressing unmet needs in rare disease research has positioned it as a key player in the evolving biotech landscape.
---
Key Facts
---
